Clinical Trial Update: Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating single agent chemotherapy with or without nivolumab in advanced NSCLC patients with primary resistance to prior PD-1/PD-L1 inhibitors; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• Chemotherapy (single agent)
• nivolumab (nivolumab)

Snippet

Sponsor: Nasser Hanna, M.D. | Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung | Phase 2 | Status: TERMINATED | Results posted: 2019-11-29